Activator protein-1 in liver pathology: from precancerous diseases to hepatocellular carcinoma

Abstract

Activator protein 1 (AP-1) is a family of transcription factors composed of Jun, Fos, activating transcription factor (ATF), and musculoaponeurotic fibrosarcoma (MAF) homodimers and heterodimers that regulate diverse cellular processes such as proliferation, apoptosis, differentiation, survival, and migration. Accordingly, AP-1 plays an essential role in several diseases including cancer. During liver cancer development, AP-1 abnormal activation has been implicated from cancer initiation to cancer progression. This review aims to provide a current integrative understanding of the role of AP-1 in liver carcinogenesis and suggests potential settings for its clinical use in diagnosis and treatment. Novel AP-1-based therapeutic approaches deserve further investigation and clinical application for the benefit of liver cancer patients.

Keywords

Activator protein-1 / liver pathology / hepatocellular carcinoma / liver carcinogenesis / transcription factors

References

[1] Ye N,Wild C,Zhou J.Small molecule inhibitors targeting activator protein 1 (AP-1).J Med Chem2014;57:6930-48 PMCID:PMC4148154

[2] Manning AM.Targeting JNK for therapeutic benefit: from junk to gold?.Nat Rev Drug Discov2003;2:554-65

[3] Shaulian E.AP-1 as a regulator of cell life and death.Nat Cell Biol2002;4:E131-6

[4] Bejjani F,Zibara K,Jariel-Encontre I.The AP-1 transcriptional complex: local switch or remote command?.Biochim Biophys Acta Rev Cancer2019;1872:11-23

[5] Brennan A,Kad NM.Selective antagonism of cJun for cancer therapy.J Exp Clin Cancer Res2020;39:184 PMCID:PMC7488417

[6] Bhosale PB,Abusaliya A.Structural and functional properties of activator protein-1 in cancer and inflammation.Evid Based Complement Alternat Med2022;2022:9797929 PMCID:PMC9162854

[7] Eferl R.AP-1: a double-edged sword in tumorigenesis.Nat Rev Cancer2003;3:859-68

[8] Eferl R,Kenner L.Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53.Cell2003;112:181-92

[9] Schulien I,Schmitt-Graeff A.The transcription factor c-Jun/AP-1 promotes liver fibrosis during non-alcoholic steatohepatitis by regulating Osteopontin expression.Cell Death Differ2019;26:1688-99 PMCID:PMC6748141

[10] Videla LA,Rodrigo R.Liver NF-kappaB and AP-1 DNA binding in obese patients.Obesity2009;17:973-9

[11] Min L,Bakiri L.Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin.Nat Cell Biol2012;14:1203-11

[12] Fiorentino F,Favale G,Mai A.The two-faced role of SIRT6 in cancer.Cancers2021;13:1156 PMCID:PMC7962659

[13] Dorn C,Saugspier M.Increased expression of c-Jun in nonalcoholic fatty liver disease.Lab Invest2014;94:394-408

[14] Lau TYH,Liong EC,Leung TM.Hepatic response to chronic hypoxia in experimental rat model through HIF-1 alpha, activator protein-1 and NF-kappa B.Histol Histopatho2013;28:463-71.

[15] El-Tanani MK,Kurisetty V,McCann M.The regulation and role of osteopontin in malignant transformation and cancer.Cytokine Growth Factor Rev2006;17:463-74

[16] Wai PY.Osteopontin: regulation in tumor metastasis.Cancer Metastasis Rev2008;27:103-18

[17] Syn WK,Liaskou E.Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis.Hepatology2011;53:106-15 PMCID:PMC3025083

[18] Kireva T,Tiegs G.Transcription factor Fra-1 induces cholangitis and liver fibrosis.Hepatology2011;53:1259-69

[19] Hasenfuss SC,Thomsen MK,Wagner EF.Activator protein 1 transcription factor Fos-related antigen 1 (Fra-1) is dispensable for murine liver fibrosis, but modulates xenobiotic metabolism.Hepatology2014;59:261-73

[20] Chen H,Wan J.PPAR-γ signaling in nonalcoholic fatty liver disease: pathogenesis and therapeutic targets.Pharmacol Ther2023;245:108391

[21] Hasenfuss SC,Thomsen MK,Auwerx J.Regulation of steatohepatitis and PPARγ signaling by distinct AP-1 dimers.Cell Metab2014;19:84-95 PMCID:PMC4023468

[22] Wu Q,Fu B,Wang X.JNK signaling in cancer cell survival.Med Res Rev2019;39:2082-104

[23] Schattenberg JM,Wang Y.JNK1 but not JNK2 promotes the development of steatohepatitis in mice.Hepatology2006;43:163-72

[24] Steensels S,Ersoy BA.Transcriptional regulation in non-alcoholic fatty liver disease.Metabolites2020;10:283 PMCID:PMC7408131

[25] Johnson R,Hanahan D.Cellular transformation and malignancy induced by ras require c-jun.Mol Cell Biol1996;16:4504-11 PMCID:PMC231449

[26] Talotta F,Bossis G.Heterodimerization with Fra-1 cooperates with the ERK pathway to stabilize c-Jun in response to the RAS oncoprotein.Oncogene2010;29:4732-40

[27] Delire B.The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications.Eur J Clin Invest2015;45:609-23

[28] Singh R,Xiang Y,Gaarde WA.Differential effects of JNK1 and JNK2 inhibition on murine steatohepatitis and insulin resistance.Hepatology2009;49:87-96 PMCID:PMC2614457

[29] Czaja MJ.JNK regulation of hepatic manifestations of the metabolic syndrome.Trends Endocrinol Metab2010;21:707-13 PMCID:PMC2991513

[30] Cho SS,Lee JH.Ferroptosis contribute to hepatic stellate cell activation and liver fibrogenesis.Free Radic Biol Med2022;193:620-37

[31] Roeb E.Matrix metalloproteinases and liver fibrosis (translational aspects).Matrix Biol2018;68-69:463-73

[32] Xu H,Pan X.TIMP-1 expression induced by IL-32 is mediated through activation of AP-1 signal pathway.Int Immunopharmacol2016;38:233-7

[33] Lebeaupin C,Hazari Y,Chevet E.Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease.J Hepatol2018;69:927-47

[34] Zhang J,Yang N,Hu T.Endoplasmic reticulum stress-mediated cell death in liver injury.Cell Death Dis2022;13:1051 PMCID:PMC9763476

[35] Sharma RS,Kisielewski D.Experimental nonalcoholic steatohepatitis and liver fibrosis are ameliorated by pharmacologic activation of Nrf2 (NF-E2 p45-related factor 2).Cell Mol Gastroenterol Hepatol2018;5:367-98 PMCID:PMC5852394

[36] Olivares S,Henkel AS.Endoplasmic reticulum stress activates the hepatic activator protein 1 complex via mitogen activated protein kinase-dependent signaling pathways.PLoS One2014;9:e103828 PMCID:PMC4117566

[37] Zahra M,Moustafa A.Transcriptional regulatory networks in hepatitis C virus-induced hepatocellular carcinoma.Sci Rep2018;8:14234 PMCID:PMC6155139

[38] Kato N,Ono-Nita SK.Activation of intracellular signaling by hepatitis B and C viruses: C-viral core is the most potent signal inducer.Hepatology2000;32:405-12

[39] Trierweiler C,Zatloukal K.The transcription factor c-JUN/AP-1 promotes HBV-related liver tumorigenesis in mice.Cell Death Differ2016;23:576-82 PMCID:PMC4986630

[40] Tsutsumi T,Moriya K.Alteration of intrahepatic cytokine expression and AP-1 activation in transgenic mice expressing hepatitis C virus core protein.Virology2002;304:415-24

[41] Ren JH,Zhang ZZ.Sirtuin 1 regulates hepatitis B virus transcription and replication by targeting transcription factor AP-1.J Virol2014;88:2442-51 PMCID:PMC3958108

[42] Tanaka Y,Ichimura T.The hepatitis B virus X protein enhances AP-1 activation through interaction with Jab1.Oncogene2006;25:633-42

[43] Hayashi M,Chen M.Interaction of the hepatitis B virus X protein with the lysine methyltransferase SET and MYND domain-containing 3 induces activator protein 1 activation.Microbiol Immunol2016;60:17-25

[44] Kong GY,Zhang S,Ye LH.Hepatitis B virus X protein promotes hepatoma cell proliferation via upregulation of MEKK2.Acta Pharmacol Sin2011;32:1173-80 PMCID:PMC4003298

[45] Cho HK,Kyaw YY.HBx induces the proliferation of hepatocellular carcinoma cells via AP1 over-expressed as a result of ER stress.Biochem J2015;466:115-21

[46] Junli Z,Yajuan Z,Jiahuan L.The role and mechanism of CREBH regulating SIRT3 in metabolic associated fatty liver disease.Life Sci2022;306:120838

[47] Wang CH,Qiang WM.Activator protein-1 is a novel regulator of mesencephalic astrocyte-derived neurotrophic factor transcription.Mol Med Rep2018;18:5765-74

[48] Deng L,Ariffianto A.Hepatitis C virus-induced ROS/JNK signaling pathway activates the E3 ubiquitin ligase itch to promote the release of HCV particles via polyubiquitylation of VPS4A.J Virol2022;96:e0181121 PMCID:PMC8941892

[49] Ariffianto A,Harada S,Matsui C.Transcription factor JunB suppresses hepatitis C virus replication.Kobe J Med Sci2023;69:E86-95. PMCID:PMC10695097

[50] Hanahan D.Hallmarks of cancer: the next generation.Cell2011;144:646-74

[51] Hanahan D.Hallmarks of cancer: new dimensions.Cancer Discov2022;12:31-46

[52] Ameyar M,Weitzman JB.A role for AP-1 in apoptosis: the case for and against.Biochimie2003;85:747-52

[53] Stepniak E,Eferl R.C-Jun/AP-1 controls liver regeneration by repressing p53/p21 and p38 MAPK activity.Gene Dev2006;20:2306-14. PMCID:PMC1553212

[54] Moya IM.Hippo-YAP/TAZ signalling in organ regeneration and regenerative medicine.Nat Rev Mol Cell Biol2019;20:211-26

[55] Zhang S.Role of the transcriptional coactivators YAP/TAZ in liver cancer.Curr Opin Cell Biol2019;61:64-71

[56] Zanconato F,Battilana G.Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth.Nat Cell Biol2015;17:1218-27 PMCID:PMC6186417

[57] Koo JH,Meng Z.Induction of AP-1 by YAP/TAZ contributes to cell proliferation and organ growth.Genes Dev2020;34:72-86 PMCID:PMC6938666

[58] Pawlonka J,Ambroziak U.The regulation of cyclin D promoters - review.Cancer Treat Res Commun2021;27:100338

[59] Núñez KG,Thevenot PT.Cyclin D1 in the liver: role of noncanonical signaling in liver steatosis and hormone regulation.Ochsner J2017;17:56-65 PMCID:PMC5349637

[60] Deane NG,Aramandla R.Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mice.Cancer Res2001;61:5389-95

[61] Che Y,Xu R.Co-expression of XIAP and cyclin D1 complex correlates with a poor prognosis in patients with hepatocellular carcinoma.Am J Pathol2012;180:1798-807

[62] Liu Z,Al-Salman A.Epidermal growth factor induces tumour marker AKR1B10 expression through activator protein-1 signalling in hepatocellular carcinoma cells.Biochem J2012;442:273-82

[63] DiStefano JK.Diagnostic and prognostic potential of AKR1B10 in human hepatocellular carcinoma.Cancers2019;11:486 PMCID:PMC6521254

[64] Wang YY,Zhong JH.High expression of AKR1B10 predicts low risk of early tumor recurrence in patients with hepatitis B virus-related hepatocellular carcinoma.Sci Rep2017;7:42199 PMCID:PMC5299837

[65] Geng N,Li Y,Bai H.AKR1B10 inhibitor epalrestat facilitates sorafenib-induced apoptosis and autophagy via targeting the mTOR pathway in hepatocellular carcinoma.Int J Med Sci2020;17:1246-56 PMCID:PMC7294918

[66] Li Q,Shao D.Mucin1 mediates autocrine transforming growth factor beta signaling through activating the c-Jun N-terminal kinase/activator protein 1 pathway in human hepatocellular carcinoma cells.Int J Biochem Cell Biol2015;59:116-25

[67] Tu S,Huang C,Yan X.Contextual regulation of TGF-β signaling in liver cancer.Cells2019;8:1235 PMCID:PMC6829617

[68] Han D,Qin B.Upregulation of Nogo-B by hypoxia inducible factor-1 and activator protein-1 in hepatocellular carcinoma.Cancer Sci2021;112:2728-38 PMCID:PMC8253276

[69] Rao J,Zhou H.Nogo-B is a key mediator of hepatic ischemia and reperfusion injury.Redox Biol2020;37:101745 PMCID:PMC7582106

[70] Dong C,Long F.Nogo-B receptor promotes the chemoresistance of human hepatocellular carcinoma via the ubiquitination of p53 protein.Oncotarget2016;7:8850-65 PMCID:PMC4891009

[71] Dong C,Jiang K.The Nogo-B receptor promotes human hepatocellular carcinoma cell growth via the Akt signal pathway.J Cell Biochem2018;119:7738-46 PMCID:PMC7328129

[72] Bakiri L,Guío-Carrión A,Hasselblatt P.Liver cancer development driven by the AP-1/c-Jun~Fra-2 dimer through c-Myc.Proc Natl Acad Sci U S A2024;121:e2404188121 PMCID:PMC11067056

[73] Maulik N,Galang N.Differential regulation of Bcl-2, AP-1 and NF-kappaB on cardiomyocyte apoptosis during myocardial ischemic stress adaptation.FEBS Lett1999;443:331-6

[74] Takeuchi K,Ito F.Role of transcription factor activator protein 1 (AP1) in epidermal growth factor-mediated protection against apoptosis induced by a DNA-damaging agent.FEBS J2006;273:3743-55

[75] Qiao Y,Jonsson P,Zhao C.AP-1 is a key regulator of proinflammatory cytokine TNFα-mediated triple-negative breast cancer progression.J Biol Chem2016;291:18309 PMCID:PMC5000078

[76] Jang J,Kim JW,Kim HG.Anti-inflammatory activities of an anti-histamine drug, loratadine, by suppressing TAK1 in AP-1 pathway.Int J Mol Sci2022;23:3986 PMCID:PMC8999734

[77] Kyriakis JM.Activation of the AP-1 transcription factor by inflammatory cytokines of the TNF family.Gene Exp1999;7:217-31 PMCID:PMC6174675

[78] Thomsen MK,Hasenfuss SC,Martinez L.JUNB/AP-1 controls IFN-γ during inflammatory liver disease.J Clin Invest2013;123:5258-68 PMCID:PMC3859404

[79] Hasselblatt P,Komnenovic V,Wagner EF.Hepatocyte survival in acute hepatitis is due to c-Jun/AP-1-dependent expression of inducible nitric oxide synthase.Proc Natl Acad Sci U S A2007;104:17105-10 PMCID:PMC2040484

[80] Zhuo B,Xie T.Integrative epigenetic analysis reveals AP-1 promotes activation of tumor-infiltrating regulatory T cells in HCC.Cell Mol Life Sci2023;80:103 PMCID:PMC11071886

[81] Pinter M,Pinato DJ.Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice.Lancet Gastroenterol Hepatol2023;8:760-70

[82] Doorn DJ, Takkenberg RB, Klümpen HJ. Immune checkpoint inhibitors in hepatocellular carcinoma: an overview.Pharmaceuticals2020;14:3 PMCID:PMC7821931

[83] Venkatraman S,Hongeng S,Chutipongtanate S.Transcriptional regulation of cancer immune checkpoints: emerging strategies for immunotherapy.Vaccines2020;8:735 PMCID:PMC7761936

[84] Xiao G,Liu H,Liu X.Activator protein 1 suppresses antitumor T-cell function via the induction of programmed death 1.Proc Natl Acad Sci U S A2012;109:15419-24 PMCID:PMC3458364

[85] You X,Binder M.Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation.Blood2022;139:1066-79 PMCID:PMC8854684

[86] Luo B,Tan D,Lin J.Anlotinib benefits the αPDL1 immunotherapy by activating ROS/JNK/AP-1 pathway to upregulate PDL1 expression in colorectal cancer.Oxid Med Cell Longev2022;2022:8965903 PMCID:PMC9553391

[87] Yu P,Li K.The traditional chinese medicine monomer Ailanthone improves the therapeutic efficacy of anti-PD-L1 in melanoma cells by targeting c-Jun.J Exp Clin Cancer Res2022;41:346 PMCID:PMC9753288

[88] Hsiang CY,Chen JC.Acetaldehyde induces matrix metalloproteinase-9 gene expression via nuclear factor-kappaB and activator protein 1 signaling pathways in human hepatocellular carcinoma cells: association with the invasive potential.Toxicol Lett2007;171:78-86

[89] Arii S,Harada T.Overexpression of matrix metalloproteinase 9 gene in hepatocellular carcinoma with invasive potential.Hepatology1996;24:316-22

[90] Nart D,Yilmaz F,Karasu Z.Expression of matrix metalloproteinase-9 in predicting prognosis of hepatocellular carcinoma after liver transplantation.Liver Transpl2010;16:621-30

[91] Pan MH,Chen WJ,Badmaev V.Pterostilbene inhibited tumor invasion via suppressing multiple signal transduction pathways in human hepatocellular carcinoma cells.Carcinogenesis2009;30:1234-42

[92] Lee KH,Kao ST.The inhibitory effect of hesperidin on tumor cell invasiveness occurs via suppression of activator protein 1 and nuclear factor-kappaB in human hepatocellular carcinoma cells.Toxicol Lett2010;194:42-9

[93] Yu MH.Hydroquinone stimulates cell invasion through activator protein-1-dependent induction of MMP-9 in HepG2 human hepatoma cells.Food Chem Toxicol2016;89:120-5

[94] Cho SB,Park SJ.KITENIN is associated with activation of AP-1 target genes via MAPK cascades signaling in human hepatocellular carcinoma progression.Oncol Res2011;19:115-23

[95] Sugioka Y,Inagaki Y.c-Jun NH2-terminal kinase pathway is involved in constitutive matrix metalloproteinase-1 expression in a hepatocellular carcinoma-derived cell line.Int J Cancer2004;109:867-74

[96] Yoon JH,Lee SG.Ginsenoside Rh1 suppresses matrix metalloproteinase-1 expression through inhibition of activator protein-1 and mitogen-activated protein kinase signaling pathway in human hepatocellular carcinoma cells.Eur J Pharmacol2012;679:24-33

[97] Geervliet E.Matrix metalloproteinases as potential biomarkers and therapeutic targets in liver diseases.Cells2020;9:1212 PMCID:PMC7290342

[98] Rhee H,Choi JH.Keratin 19 expression in hepatocellular carcinoma is regulated by fibroblast-derived HGF via a MET-ERK1/2-AP1 and SP1 axis.Cancer Res2018;78:1619-31

[99] Zhu Q,Hu Y.miR-21 promotes migration and invasion by the miR-21-PDCD4-AP-1 feedback loop in human hepatocellular carcinoma.Oncol Rep2012;27:1660-8

[100] Liu JJ,Yang XJ.A novel AP-1/miR-101 regulatory feedback loop and its implication in the migration and invasion of hepatoma cells.Nucleic Acids Res2014;42:12041-51 PMCID:PMC4231742

[101] Xian L,Qin L.Jun/Fos promotes migration and invasion of hepatocellular carcinoma cells by enhancing BORIS promoter activity.Int J Biochem Cell Biol2024;169:106540

[102] Liu Y,Cheng Y.ASIC1 promotes migration and invasion of hepatocellular carcinoma via the PRKACA/AP-1 signaling pathway.Carcinogenesis2024;45:399-408

[103] Catar R,Wagner P.The proto-oncogene c-Fos transcriptionally regulates VEGF production during peritoneal inflammation.Kidney Int2013;84:1119-28

[104] Ji L,Shi L,Lu B.Andrographolide decreased VEGFD expression in hepatoma cancer cells by inducing ubiquitin/proteasome-mediated cFos protein degradation.Biochim Biophys Acta2015;1850:750-8

[105] Cai H,Liu X.Nogo-B promotes tumor angiogenesis and provides a potential therapeutic target in hepatocellular carcinoma.Mol Oncol2018;12:2042-54 PMCID:PMC6275258

[106] Li YK,Wu DC,Tang S.Nogo-B receptor in relevant carcinoma: current achievements, challenges and aims (review).Int J Oncol2018;53:1827-35

[107] Acun T,Habermann JK.HLJ1 (DNAJB4) gene is a novel biomarker candidate in breast cancer.OMICS2017;21:257-65 PMCID:PMC5586162

[108] Chen CH,Su KY.HLJ1 is an endogenous Src inhibitor suppressing cancer progression through dual mechanisms.Oncogene2016;35:5674-85

[109] Wang CC,Dai TH.Synergistic activation of the tumor suppressor, HLJ1, by the transcription factors YY1 and activator protein 1.Cancer Res2007;67:4816-26

[110] Martínez-Zamudio RI,de Freitas JANLF.AP-1 imprints a reversible transcriptional programme of senescent cells.Nat Cell Biol2020;22:842-55 PMCID:PMC7899185

[111] Wang Y,Song Y,Deng H.Unveiling E2F4, TEAD1 and AP-1 as regulatory transcription factors of the replicative senescence program by multi-omics analysis.Protein Cell2022;13:742-59 PMCID:PMC9233726

[112] Jachim SK,Ordog T.BMAL1 modulates senescence programming via AP-1.Aging2023;15:9984-10009 PMCID:PMC10599731

[113] Han R,Ugalde AP.Functional CRISPR screen identifies AP1-associated enhancer regulating FOXF1 to modulate oncogene-induced senescence.Genome Biol2018;19:118 PMCID:PMC6097335

[114] Dabrowska M,Dabrowski M.Antigen presentation capability and AP-1 activation accompany methotrexate-induced colon cancer cell senescence in the context of aberrant β-catenin signaling.Mech Ageing Dev2021;197:111517

[115] Bu X,Jia F.Synergistic effect of mTOR inhibitor rapamycin and fluorouracil in inducing apoptosis and cell senescence in hepatocarcinoma cells.Cancer Biol Ther2008;7:392-6

[116] Yogev O,Inoue K.Induction of transcriptionally active Jun proteins regulates drug-induced senescence.J Biol Chem2006;281:34475-83

[117] Liu P,Legrand A.Activation of NF-kappa B, AP-1 and STAT transcription factors is a frequent and early event in human hepatocellular carcinomas.J Hepatol2002;37:63-71

[118] Chen YL,Lin PY.The expression of a tumor suppressor gene JDP2 and its prognostic value in hepatocellular carcinoma patients.Hum Pathol2017;63:212-6

[119] Bitton-Worms K,Aronheim A.The AP-1 repressor protein, JDP2, potentiates hepatocellular carcinoma in mice.Mol Cancer2010;9:54 PMCID:PMC2841123

[120] Daschner PJ,Plouzek CA.Increased AP-1 activity in drug resistant human breast cancer MCF-7 cells.Breast Cancer Res Treat1999;53:229-40

[121] Wang Y,Wu YM.AP-1 confers resistance to anti-cancer therapy by activating XIAP.Oncotarget2018;9:14124-37 PMCID:PMC5865658

[122] Tang W,Zhang W.The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects.Signal Transduct Target Ther2020;5:87 PMCID:PMC7292831

[123] Cabral LKD,Sukowati CHC.Sorafenib resistance in hepatocellular carcinoma: the relevance of genetic heterogeneity.Cancers2020;12:1576 PMCID:PMC7352671

[124] Cheng BY,Leung HW.IRAK1 augments cancer stemness and drug resistance via the AP-1/AKR1B10 signaling cascade in hepatocellular carcinoma.Cancer Res2018;78:2332-42

[125] Yan D,Dai X.Activation of AKT/AP1/FoxM1 signaling confers sorafenib resistance to liver cancer cells.Oncol Rep2019;42:785-96

[126] Song D,Zhang L.The potential of activator protein 1 (AP-1) in cancer targeted therapy.Front Immunol2023;14:1224892 PMCID:PMC10361657

[127] Kamide D,Araki K.Selective activator protein-1 inhibitor T-5224 prevents lymph node metastasis in an oral cancer model.Cancer Sci2016;107:666-73 PMCID:PMC4970834

[128] Fukuda K,Mutoh M,Akao S.Inhibition of activator protein 1 activity by berberine in human hepatoma cells.Planta Med1999;65:381-3

[129] Tang S,Li J.The selective activator protein-1 inhibitor T-5224 regulates the IRF4/MYC axis and exerts cooperative antimyeloma activity with bortezomib.Chem Biol Interact2023;384:110687

[130] Tewari D,Nabavi SM.Targeting activator protein 1 signaling pathway by bioactive natural agents: possible therapeutic strategy for cancer prevention and intervention.Pharmacol Res2018;128:366-75

[131] Li XJ,Ju LG.Deficiency of histone methyltransferase SET domain-containing 2 in liver leads to abnormal lipid metabolism and HCC.Hepatology2021;73:1797-815

[132] Meijer CA,van Dijk RA.Activator protein-1 (AP-1) signalling in human atherosclerosis: results of a systematic evaluation and intervention study.Clin Sci2012;122:421-8 PMCID:PMC3259695

[133] Verborg W,Bissett D.First-into-man phase I and pharmacokinetic study of XR5944.14, a novel agent with a unique mechanism of action.Br J Cancer2007;97:844-50 PMCID:PMC2360398

[134] Suchitha GP,Prasad TSK.A signaling network map of lipoxin (LXA4): an anti-inflammatory molecule.Inflamm Res2024;73:1099-106

[135] Liu M,Hu Z,Zhang Y.Targeting MyD88: therapeutic mechanisms and potential applications of the specific inhibitor ST2825.Inflamm Res2023;72:2023-36

[136] Skrzycki M,Podsiad M.[Protein level of transcription factors AP-1 and NF-kappaB in selected human gastrointestinal tract tumors].Pol Merkur Lekarski2008;25:510-15.

[137] Columbano A,Pibiri M.Increased expression of c-fos, c-jun and LRF-1 is not required for in vivo priming of hepatocytes by the mitogen TCPOBOP.Oncogene1997;14:857-63

[138] Innes H.Statistical perspectives on using hepatocellular carcinoma risk models to inform surveillance decisions.J Hepatol2023;79:1332-7

[139] Xu F,Tong CSW.A combinatorial CRISPR-Cas9 screen identifies ifenprodil as an adjunct to sorafenib for liver cancer treatment.Cancer Res2021;81:6219-32

[140] Israelsen M,Tsochatzis EA.Steatotic liver disease.Lancet2024;404:1761-78